share_log

Unpacking the Latest Options Trading Trends in Eli Lilly

Unpacking the Latest Options Trading Trends in Eli Lilly

揭示了Eli Lilly最新期權交易趨勢
Benzinga ·  09/17 10:16

Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly.

擁有大量資金的鯨魚對Eli Lilly採取了明顯看淡的立場。

Looking at options history for Eli Lilly (NYSE:LLY) we detected 30 trades.

通過查看Eli Lilly(紐交所:LLY)的期權歷史,我們發現了30筆交易。

If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 43% with bearish.

如果我們考慮每筆交易的具體情況,可以準確地說,30%的投資者持看漲期望,43%持看跌期望。

From the overall spotted trades, 4 are puts, for a total amount of $423,567 and 26, calls, for a total amount of $4,363,478.

從總體來看,有4個看跌期權交易,總金額爲423,567美元,還有26個看漲期權交易,總金額爲4,363,478美元。

Projected Price Targets

預計價格目標

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $700.0 to $1100.0 for Eli Lilly during the past quarter.

通過分析這些合約的成交量和持倉量,似乎大戶在過去的一個季度裏關注Eli Lilly的股價區間是700.0到1100.0美元之間。

Insights into Volume & Open Interest

成交量和持倉量分析

In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 498.6 with a total volume of 1,460.00.

在流動性和關注度方面,今天Eli Lilly的期權交易平均持倉量爲498.6,總成交量爲1,460.00。

In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $700.0 to $1100.0 over the last 30 days.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $700.0 to $1100.0 over the last 30 days.

Eli Lilly Call and Put Volume: 30-Day Overview

Eli Lilly Call and Put Volume: 30-Day Overview

1726582568_0.png

Significant Options Trades Detected:

檢測到重大期權交易:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
LLY CALL SWEEP BEARISH 11/15/24 $223.4 $217.55 $220.0 $700.00 $2.2M 836 300
LLY CALL SWEEP NEUTRAL 01/17/25 $81.9 $80.95 $81.9 $900.00 $311.3K 1.8K 46
LLY PUT SWEEP BULLISH 10/18/24 $28.3 $25.0 $25.0 $900.00 $300.4K 883 2
LLY CALL SWEEP NEUTRAL 01/17/25 $119.15 $115.4 $119.15 $840.00 $273.9K 459 7
LLY CALL TRADE BEARISH 11/15/24 $51.65 $48.8 $48.8 $930.00 $239.1K 535 100
標的 看跌/看漲 交易類型 情緒 到期日 賣盤 買盤 價格 執行價格 總交易價格 未平倉合約數量 成交量
LLY 看漲 SWEEP 看淡 11/15/24 $223.4 $217.55 $220.0 $700.00 $2.2M 836 300
LLY 看漲 SWEEP 中立 01/17/25 $81.9 80.95美元 $81.9 $900.00 311.3K美元 1.8K 46
LLY 看跌 SWEEP 看好 10/18/24 $28.3 $25.0 $25.0 $900.00 300.4千美元 883 2
LLY 看漲 SWEEP 中立 01/17/25 $119.15 $115.4 $119.15 $840.00 $273.9K 459 7
LLY 看漲 交易 看淡 11/15/24 $51.65 48.8美元 48.8美元 $930.00 成交量爲239.1K 535 100

About Eli Lilly

關於Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly是一家專注於神經科學,心臟代謝,癌症和免疫學的藥物公司。Lilly的主要產品包括用於治療癌症的Verzenio;用於心臟代謝的Mounjaro,Zepbound,Jardiance,Trulicity,Humalog和Humulin;以及用於免疫學的Taltz和Olumiant。

Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.

在對Eli Lilly的期權活動進行分析後,我們轉向更仔細地觀察該公司的業績。

Present Market Standing of Eli Lilly

Eli Lilly目前的市場地位

  • Currently trading with a volume of 365,615, the LLY's price is down by -1.32%, now at $911.36.
  • RSI readings suggest the stock is currently may be approaching oversold.
  • Anticipated earnings release is in 44 days.
  • 目前交易量爲365,615,LLY的價格下跌-1.32%,現在爲$911.36。
  • RSI讀數表明該股票目前可能接近超賣狀態。
  • 預期四十四天後公佈收益。

Professional Analyst Ratings for Eli Lilly

Eli Lilly的專業分析師評級

5 market experts have recently issued ratings for this stock, with a consensus target price of $1007.2.

有5位市場專家最近對這隻股票發表了評級意見,達成共識目標價爲$1007.2。

  • In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885.
  • Reflecting concerns, an analyst from Citigroup lowers its rating to Buy with a new price target of $1060.
  • Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100.
  • In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $885.
  • An analyst from Morgan Stanley has revised its rating downward to Overweight, adjusting the price target to $1106.
  • 爲了謹慎起見,Cantor Fitzgerald的分析師將其評級下調爲超重,設定了885美元的價格目標。
  • 反映擔憂,花旗集團的一位分析師將其評級下調爲買入,目標價爲$1060。
  • JP摩根的分析師在對Eli Lilly的評估一致性上保持超額評級,目標價爲$1100。
  • 爲了謹慎起見,Cantor Fitzgerald的分析師將其評級下調爲超重,設定了885美元的價格目標。
  • 摩根士丹利的一位分析師將其評級下調爲增持,並將目標價調至1106美元。

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with Benzinga Pro for real-time alerts.

交易期權具有更高的風險,但也提供了更高的利潤潛力。睿智的交易者通過不斷的教育、策略性交易調整、利用各種因子並對市場動態保持敏感來減輕這些風險。通過使用Benzinga Pro,及時關注Eli Lilly的最新期權交易並獲得實時提醒。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論